Cipla

Cipla Ltd.
Mumbai Central
Mumbai 400 008

9th August, 2013

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBERG
Societe Anonyme
11, av de la Porte-Neuve,
L-2227 Luxemberg

Dear Sirs,

Please find enclosed copy of Press Release dated 9th August, 2013.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited

M. A. Sanghvi

Mital Sanghvi
Company Secretary

Encl: as above

Phone : (9122) 23082891, 23095521 • Fax : (9122) 23070013, 23070393, 23070385


Press Release


Cipla announces Q1 FY 1314Unaudited Financial Results


Mumbai, India, 9thAugust 2013: Cipla Limited (BSE: 500087, NSE: CIPLA) todayannounceditsUnaudited Financial Results for the quarter endedJune 30, 2013 (Q1).


Key Financial & Performance HighlightsQ1 FY1314vis-a-visQ1 FY1213:

- Gross revenues grew by 25.3% to ₹2492cr, up from ₹1989cr
- Operating margins grew by 24.8% to ₹675cr, up from ₹541cr
- Profit after tax grew by 18.5% to ₹475cr, upfrom ₹401cr









Profit & Loss Highlights:

- Material cost is at 40.8% of Total Sales in Q1 FY1314 as compared to 37.6% in Q1 FY1213.
- Operating margins increased by 24.8% and is at 27.1% of Income from Operations during Q1 FY1314.
- Profit after tax increased by 18.5% to ₹475cr during Q1 FY1314 as compared to ₹401cr during Q1 FY1213.

Performance Review:

Domestic business:

- Domestic revenues grew by 16.7% to ₹1132cr during Q1 FY1314, up from ₹970cr during Q1 FY1213.
- The growth in domestic revenues was largely on account of growth in anti-asthma, anti-biotics/infectives, and cardiovascular therapy segments.

International business:

- Exports of formulations grew by 27.7% to ₹1034cr during Q1 FY1314, up from ₹810cr during Q1 FY1213.
- Exports of APIs fell by 13.1% to ₹146cr during Q1 FY1314, from ₹168cr during Q1 FY1213.
- The growth in export revenues was primarily due to growth in anti-retroviral, anti-asthma and anti-allergic segments.

About Cipla:
Cipla laid foundations for the Indian pharmaceutical industry back in 1935 with the vision to make India self-reliant in healthcare. Over the years Cipla has emerged as one of the most respected names not just in India but worldwide. Its state of the art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. With over 34 manufacturing units across the country, Cipla manufactures over 2000 products in 65 therapies.

With a turnover of over US$ 1.5 billion, Cipla serves doctors and patients in over 170 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices. (www.cipla.com).

Media Contact:

Finance	**Corporate Communications**
Ajay Luharuka	Jaisingh Balakrishnan
Contact No.: 022 – 23025435	Contact No.: 022 - 23025813
E-Mail: ajay@cipla.com	E Mail: jaisingh.krishnan@cipla.com